

Registered Office:

Office No.: 301, 3rd Floor, Konark Icon, Mundhwa-Kharadi Road,
Kirtane Baugh, Magarpatta, Hadapsar, Pune, Maharashtra, Pincode-411028.
Email: enquiry@cian.co
Mobile No.: +919049000648 Website: www.cian.co

Corporate Office:

606, Ring Road Mall, Sector-3, Rohini, New Delhi, Pincode-110085.
Landline No.: 011-49120841

Factory: Khasra No.: 245 & 248, Village Sisona, Bhagwanpur,
Roorkee, District Haridwar, Uttarakhand, Pincode-247661.

Mobile No.: +917830655000

CIN: L24233PN2003PLC017563

Ref. No.: CIAN/BSE/2026-27/30

Friday, October 23, 2026

To,
The Manager – Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai – 400 001

Scrip Code: 542678

Trading Symbol: CHCL

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Approval of Resolution Plan of Dr. Smiths Biotech Private Limited, Wholly Owned Subsidiary of the Company, by the Hon'ble National Company Law Tribunal, and consequent cessation from being a subsidiary of Cian Healthcare Limited.

Dear Sir/Madam,

In compliance with the relevant provisions of Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**LODR Regulations**"), and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/II/3762/2026 dated January 30, 2026, Cian Healthcare Limited ("**Company**") hereby inform that Dr. Smiths Biotech Private Limited ("**Dr. Smith**" or "**Corporate Debtor**"), a wholly owned subsidiary of the Company, was admitted into the Corporate Insolvency Resolution Process ("**CIRP**") upon filing of application by Small Industries Development Bank of India ("**Financial Creditor**") under the provisions of Section 7 of the Insolvency and Bankruptcy Code, 2016 ("**IBC**" or "**Code**"), before the Hon'ble National Company Law Tribunal, Mumbai Bench-III ("**NCLT**").

The Hon'ble NCLT, vide its order dated September 23, 2026 ("**NCLT Order**"), approved the resolution plan ("**Approved Resolution Plan**" or "**Plan**") submitted by Ananta Medicare Limited ("**Successful Resolution Applicant**"), as earlier approved by the Committee of Creditors with unanimous votes, as per the provisions of the Code, on December 25, 2025.

In accordance with the relevant provisions of the NCLT Order read with the Approved Resolution Plan, the entire existing equity share capital of Dr. Smith, including the equity shares held by the Company, has been extinguished and cancelled with effect from October 23, 2026, in accordance with the decision taken by the Implementation and Monitoring Committee dated October 23, 2026, which concluded at 03:50 P.M. (IST).

The details pursuant to Regulation 30 read with Para A of Part A of Schedule III to the LODR Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/II/3762/2026 dated January 30, 2026, are provided in **Annexure - A**.

We shall continue to keep all stakeholders and regulatory authorities abreast of further material developments in this regard.

Kindly take the above information on record and oblige.

Thanking you,
Yours faithfully,
For **Cian Healthcare Limited**

**Rachit
Malhotra**

Digitally signed by
Rachit Malhotra
Date: 2026.10.23
19:03:42 +05'30'

Rachit Malhotra
Company Secretary & Chief Compliance Officer
Membership No.: A39894
Enclosed: As above

Registered Office:

Office No.: 301, 3rd Floor, Konark Icon, Mundhwa-Kharadi Road,
Kirtane Baugh, Magarpatta, Hadapsar, Pune, Maharashtra, Pincode-411028.
Email: enquiry@cian.co
Mobile No.: +919049000648 Website: www.cian.co

Corporate Office:

606, Ring Road Mall, Sector-3, Rohini, New Delhi, Pincode-110085.
Landline No.: 011-49120841

Factory: Khasra No.: 245 & 248, Village Sisona, Bhagwanpur,
Roorkee, District Haridwar, Uttarakhand, Pincode-247661.

Mobile No.: +917830655000

CIN: L24233PN2003PLC017563

ANNEXURE A

Details pursuant to Regulations 30 read with Para A of Part A of Schedule III to the LODR Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/II/3762/2026 dated January 30, 2026

S. No.	Particulars	Details
(a)	Details of any change in the Status/ any development	<p>Small Industries Development Bank of India filed an application under Section 7 of the Code before the Hon'ble NCLT against Dr. Smiths Biotech Private Limited, which was admitted vide order dated April 28, 2025, thereby initiating the CIRP of Dr. Smith. The Financial Creditor thereafter lodged a claim of INR 8,55,34,648/- (Rupees Eight Crore Fifty-Five Lakh Thirty-Four Thousand Six Hundred and Forty-Eight only) in the CIRP, of which INR 8,47,45,058/- was admitted.</p> <p>The Hon'ble NCLT, vide the NCLT Order dated September 23, 2026, approved the resolution plan submitted by Ananta Medicare Limited. Pursuant to the implementation of the Approved Resolution Plan, the entire existing equity share capital of Dr. Smith stood extinguished and cancelled on October 23, 2026 and Dr. Smith ceased to be a subsidiary of the Company with effect from that date</p>
(b)	Amount and percentage of the turnover or revenue or income and net worth contributed by the subsidiary during the last financial year	<p>Based on the audited standalone financial statements of Dr. Smiths Biotech Private Limited and the audited consolidated financial statements of the Company for FY 2025-26:</p> <ul style="list-style-type: none"> Revenue from operations contributed by Dr. Smith: NIL. Total income contributed by Dr. Smith: ₹1.03 lakhs, i.e. 0.03% of the consolidated total income of ₹2,946.87 lakhs. Net worth contributed by Dr. Smith: ₹(987.00) lakhs, i.e. (115.63)% of the consolidated net worth of ₹853.60 lakhs. The percentage exceeds 100% because the net worth contributed by Dr. Smith is negative
(c)	Date on which the agreement for sale has been entered into	Not applicable. The cessation has not arisen from any agreement for sale. The equity share capital of Dr. Smith has been extinguished and cancelled by operation of the NCLT Order read with the Approved Resolution Plan.
(d)	Expected date of completion of sale / disposal	Note applicable, there being no sale or disposal by the Company. Dr. Smith ceased to be a subsidiary of the Company with effect from October 23, 2026, upon extinguishment and cancellation of its entire existing equity share capital pursuant to the Approved Resolution Plan.
(e)	Consideration received from such sale / disposal	Nil. No consideration is receivable by the Company, the equity shares held by it in Dr. Smith having been extinguished and cancelled without any payment under the Approved Resolution Plan.
(f)	Brief details of buyers and whether any of the buyers belong to the promoter / promoter group / group companies. If yes, details thereof	<p>Resolution Applicant: Ananta Medicare Limited, a company incorporated under the Companies Act, 1956, having its registered office at 621, Ring Road Mall, Sector 3, Rohini, New Delhi – 110085 and CIN U85110DL2008PLC174677.</p> <p>The Resolution Applicant is a holding company and a promoter of the Company and does not belong to the erstwhile promoter group of Dr. Smiths Biotech Private Limited.</p>

Registered Office:

Office No.: 301, 3rd Floor, Konark Icon, Mundhwa-Kharadi Road,
Kirtane Baugh, Magarpatta, Hadapsar, Pune, Maharashtra, Pincode-411028.
Email: enquiry@cian.co
Mobile No.: +919049000648 Website: www.cian.co

Corporate Office:

606, Ring Road Mall, Sector-3, Rohini, New Delhi, Pincode-110085.
Landline No.: 011-49120841

Factory: Khasra No.: 245 & 248, Village Sisona, Bhagwanpur,
Roorkee, District Haridwar, Uttarakhand, Pincode-247661.

Mobile No.: +917830655000

CIN: L24233PN2003PLC017563

(g)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	No. The cessation arises from the NCLT Order read with the resolution plan approved by the Committee of Creditors of Dr. Smith and the Hon'ble NCLT under the IBC and does not involve any transaction between the Company and a related party.
(h)	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with Regulation 37A of LODR Regulations	Not applicable
(i)	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation / merger	Not applicable